CETP inhibition, statins and diabetes

Type 2 diabetes is a causal risk factor for the development of atherosclerotic cardiovascular disease (ASCVD). While treatment with a statin reduces the risk of having an ASCVD event in all people, including those with type-2 diabetes, statin treatment also increases the likelihood of new onset diab...

Full description

Saved in:
Bibliographic Details
Published in:Atherosclerosis 2018-11, Vol.278, p.143-146
Main Authors: Barter, Philip J., Cochran, Blake J., Rye, Kerry-Anne
Format: Article
Language:English
Subjects:
CETP inhibition
Diabetes
Statins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Type 2 diabetes is a causal risk factor for the development of atherosclerotic cardiovascular disease (ASCVD). While treatment with a statin reduces the risk of having an ASCVD event in all people, including those with type-2 diabetes, statin treatment also increases the likelihood of new onset diabetes when given to those with risk factors for developing diabetes. Treatment with the cholesteryl ester transfer protein (CETP) inhibitor, anacetrapib, reduces the risk of having a coronary event over and above that achieved with a statin. However, unlike statins, anacetrapib decreases the risk of developing diabetes. If the reduced risk of new-onset diabetes is confirmed in another CETP inhibitor outcome trial, there will be a case for considering the use of the combination of a statin plus a CETP inhibitor in high ASCVD-risk people who are also at increased risk of developing diabetes. •Treatment with a statin increases the likelihood of new onset diabetes.•Treatment with a CETP inhibitor reduces risk of new onset diabetes.
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2018.09.033